We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
XADAGO (Seqirus Pty Ltd)
Product name
XADAGO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
241 working days (255)
Active ingredients
safinamide mesilate
Registration type
NCE/NBE
Indication
XADAGO (film coated tablets) is indicated for the treatment of adult patients with fluctuating idiopathic Parkinson's disease (PD) as add-on therapy to a regimen that includes levodopa (L-Dopa).